Výsledky vyhledávání - Paal Brunsvig

  • Zobrazuji výsledky 1 - 14 z 14
Upřesnit hledání
  1. 1
    Immunological factors influencing clinical outcome in lung cancer patients after telomerase peptide vaccination

    Immunological factors influencing clinical outcome in lung cancer patients after telomerase peptide vaccination Autor Gaute L. Hansen, Gustav Gaudernack, Paal Brunsvig, Milada Cvancarova, Jon Amund Kyte

    Vydáno 2015
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  2. 2
    Telomerase Peptide Vaccination in NSCLC: A Phase II Trial in Stage III Patients Vaccinated after Chemoradiotherapy and an 8-Year Update on a Phase I/II Trial

    Telomerase Peptide Vaccination in NSCLC: A Phase II Trial in Stage III Patients Vaccinated after Chemoradiotherapy and an 8-Year Update on a Phase I/II Trial Autor Paal Brunsvig, Jon Amund Kyte, Christian Kersten, Stein Sundstrøm, Mona Møller, Marta Nyakas, Gaute L. Hansen, Gustav Gaudernack, Steinar Aamdal

    Vydáno 2011
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  3. 3
    Vinorelbine/carboplatin vs gemcitabine/carboplatin in advanced NSCLC shows similar efficacy, but different impact of toxicity

    Vinorelbine/carboplatin vs gemcitabine/carboplatin in advanced NSCLC shows similar efficacy, but different impact of toxicity Autor Nina Helbekkmo, Stein Sundstrøm, Ulf Aasebø, Paal Brunsvig, Christian von Plessen, Harald Hjelde, Oddveig K. Garpestad, Abigail Bailey, Roy M. Bremnes

    Vydáno 2007
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  4. 4
    Hypofractionated Palliative Radiotherapy (17 Gy per two fractions) in Advanced Non–Small-Cell Lung Carcinoma Is Comparable to Standard Fractionation for Symptom Control and Survival: A National Phase III Trial

    Hypofractionated Palliative Radiotherapy (17 Gy per two fractions) in Advanced Non–Small-Cell Lung Carcinoma Is Comparable to Standard Fractionation for Symptom Control and Surviva... Autor Stein Sundstrøm, Roy M. Bremnes, Ulf Aasebø, Steinar Aamdal, Reidulv Hatlevoll, Paal Brunsvig, Dag Clement Johannessen, Olbjørn Klepp, Peter Fayers, Stein Kaasa

    Vydáno 2004
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  5. 5
    Telomerase peptide vaccination: a phase I/II study in patients with non-small cell lung cancer

    Telomerase peptide vaccination: a phase I/II study in patients with non-small cell lung cancer Autor Paal Brunsvig, Steinar Aamdal, Marianne Klemp, Gunnar Kvalheim, C. J. Markowski-Grimsrud, I. Sve, Marianne Dyrhaug, Sissel Trachsel, Mona Møller, Jon Amund Eriksen, Gustav Gaudernack

    Vydáno 2006
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  6. 6
    Long-Term Outcomes of a Phase I Study With UV1, a Second Generation Telomerase Based Vaccine, in Patients With Advanced Non-Small Cell Lung Cancer

    Long-Term Outcomes of a Phase I Study With UV1, a Second Generation Telomerase Based Vaccine, in Patients With Advanced Non-Small Cell Lung Cancer Autor Paal Brunsvig, Tormod Kyrre Guren, Marta Nyakas, Claudius H. Steinfeldt-Reisse, Wenche Rasch, Jon Amund Kyte, Hedvig Vidarsdotter Juul, Steinar Aamdal, Gustav Gaudernack, Else Marit Inderberg

    Vydáno 2020
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  7. 7
    Durable and dynamic hTERT immune responses following vaccination with the long-peptide cancer vaccine UV1: long-term follow-up of three phase I clinical trials

    Durable and dynamic hTERT immune responses following vaccination with the long-peptide cancer vaccine UV1: long-term follow-up of three phase I clinical trials Autor Espen B. Ellingsen, Elin Aamdal, Tormod Kyrre Guren, Wolfgang Lilleby, Paal Brunsvig, Sara M. Mangsbo, Steinar Aamdal, Eivind Hovig, Nadia Mensali, Gustav Gaudernack, Else Marit Inderberg

    Vydáno 2022
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  8. 8
    Phase III Study by the Norwegian Lung Cancer Study Group: Pemetrexed Plus Carboplatin Compared With Gemcitabine Plus Carboplatin As First-Line Chemotherapy in Advanced Non–Small-Cell Lung Cancer

    Phase III Study by the Norwegian Lung Cancer Study Group: Pemetrexed Plus Carboplatin Compared With Gemcitabine Plus Carboplatin As First-Line Chemotherapy in Advanced Non–Small-Ce... Autor Bjørn Henning Grønberg, Roy M. Bremnes, Øystein Fløtten, Tore Amundsen, Paal Brunsvig, Harald Hjelde, Stein Kaasa, Christian von Plessen, Frøydis Stornes, Terje Tollåli, Finn Wammer, Ulf Aasebø, Stein Sundstrøm

    Vydáno 2009
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  9. 9
    Prognostic biomarkers for immunotherapy with ipilimumab in metastatic melanoma

    Prognostic biomarkers for immunotherapy with ipilimumab in metastatic melanoma Autor Marta Nyakas, Elin Aamdal, Krag Jacobsen, Tormod Kyrre Guren, Steinar Aamdal, Kirsten T. Hagene, Paal Brunsvig, Arne Yndestad, Bente Halvorsen, Kristin Austlid Taskén, Pål Aukrust, Gunhild M. Mælandsmo, Thor Ueland

    Vydáno 2019
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  10. 10
    Randomized phase II trial comparing twice daily hyperfractionated with once daily hypofractionated thoracic radiotherapy in limited disease small cell lung cancer

    Randomized phase II trial comparing twice daily hyperfractionated with once daily hypofractionated thoracic radiotherapy in limited disease small cell lung cancer Autor Bjørn Henning Grønberg, Tarje Onsøien Halvorsen, Øystein Fløtten, Odd Terje Brustugun, Paal Brunsvig, Ulf Aasebø, Roy M. Bremnes, Terje Tollåli, Kjersti Hornslien, Bjørg Y. Aksnessæther, Erik Dyb Liaaen, Stein Sundstrøm

    Vydáno 2015
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  11. 11
    Combining a Universal Telomerase Based Cancer Vaccine With Ipilimumab in Patients With Metastatic Melanoma - Five-Year Follow Up of a Phase I/IIa Trial

    Combining a Universal Telomerase Based Cancer Vaccine With Ipilimumab in Patients With Metastatic Melanoma - Five-Year Follow Up of a Phase I/IIa Trial Autor Elin Aamdal, Else Marit Inderberg, Espen B. Ellingsen, Wenche Rasch, Paal Brunsvig, Steinar Aamdal, Karen‐Marie Heintz, Daniel Vodák, Sigve Nakken, Eivind Hovig, Marta Nyakas, Tormod Kyrre Guren, Gustav Gaudernack

    Vydáno 2021
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  12. 12
    Phase 2 Study of the HSP-90 Inhibitor AUY922 in Previously Treated and Molecularly Defined Patients with Advanced Non–Small Cell Lung Cancer

    Phase 2 Study of the HSP-90 Inhibitor AUY922 in Previously Treated and Molecularly Defined Patients with Advanced Non–Small Cell Lung Cancer Autor Enriqueta Felip, Fabrice Barlési, Benjamin Besse, Quincy Chu, Leena Gandhi, Sang‐We Kim, Enric Carcereny, Lecia V. Sequist, Paal Brunsvig, C. Chouaïd, Egbert F. Smit, Harry J.M. Groen, Dong‐Wan Kim, Keunchil Park, Emin Avşar, Sebastian Szpakowski, Mikhail Akimov, Edward B. Garon

    Vydáno 2017
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  13. 13
    P2.04-27 Ph II Study of Oral Selective AXL Inhibitor Bemcentinib (BGB324) in Combination with Pembrolizumab in Patients with Advanced NSCLC

    P2.04-27 Ph II Study of Oral Selective AXL Inhibitor Bemcentinib (BGB324) in Combination with Pembrolizumab in Patients with Advanced NSCLC Autor Carlos Arce‐Lara, Edurne Arriola, Paal Brunsvig, Enric Carcereny, Manuel Dómine, K. Dragnev, Enriqueta Felip, Rosario García Campelo, Matthew Krebs, Luis Paz‐Ares, Santiago Ponce Aix, James Spicer, José Trigo, Núria Segarra, Robert A. Holt, David Micklem, Anthony Brown, Michael Chisamore, James B. Lorens

    Vydáno 2018
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  14. 14
    Safety, Antitumor Activity, and T-cell Responses in a Dose-Ranging Phase I Trial of the Oncolytic Peptide LTX-315 in Patients with Solid Tumors

    Safety, Antitumor Activity, and T-cell Responses in a Dose-Ranging Phase I Trial of the Oncolytic Peptide LTX-315 in Patients with Solid Tumors Autor James Spicer, Aurélien Marabelle, Jean‐François Baurain, Nina Louise Jebsen, Dag Erik Jøssang, Ahmad Awada, Rebecca Kristeleit, Delphine Loirat, George Lazaridis, Christiane Jungels, Paal Brunsvig, Berit Nicolaisen, Andrew Saunders, Hamina Patel, Jérôme Galon, Fabienne Hermitte, Ketil André Camilio, Brynjar Mauseth, Vibeke Sundvold, Baldur Sveinbjørnsson, Øystein Rekdal

    Vydáno 2021
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:

Vyhledávací nástroje: